Topics

Triplet Tx Ups Survival in BRAF V600E-Mutated Colorectal Cancer

08:00 EDT 4 Oct 2019 | Drugs.com

FRIDAY, Oct. 4, 2019 -- A triplet combination of therapies (encorafenib, cetuximab, and binimetinib) results in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with...

Original Article: Triplet Tx Ups Survival in BRAF V600E-Mutated Colorectal Cancer

NEXT ARTICLE

More From BioPortfolio on "Triplet Tx Ups Survival in BRAF V600E-Mutated Colorectal Cancer"

Quick Search

Relevant Topic

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...